Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained commitment to responsible pricing and business practices that put patients first, underscoring the value that Janssen’s medicines provide to patients and the national healthcare system.
Now as always, the report reflects their fundamental beliefs:
- People should have affordable access to the medicines they need, yet many do not, in part because there is a growing affordability gap between the lower net prices for insurers and the higher costs insurers charge patients.
- In 2021, the rebates, discounts and fees we provided insurers and others in the healthcare system increased to $33.9 billion. Rebates and discounts helped lower the average net price of our medicines by -2.8%.
- U.S. government programs already benefit from vigorous private-sector negotiations that result in lower net prices.
- In 2021, they increased R&D investment to $11.9 billion – 107% more than the cost of our marketing and sales efforts – driving significant medical progress for patients.
- They continue to advance sustainable solutions that put patients first and strengthen the U.S. healthcare system by combatting healthcare disparities, promoting innovation, and improving affordable access to medicines and vaccines for all.
- Working together to advance patient-centric policy reforms, they can protect the progress we have made for every patient.
They issue this report each year because open dialogue and partnership are essential to expanding affordable access for patients today and providing greater hope for patients tomorrow. They are committed to being part of sustainable solutions that put patients first.
The full Report and one-page executive summary are available on the Janssen U.S. Transparency Report website.
